PT - JOURNAL ARTICLE AU - Agrawal, Shreeya AU - Fanton, Alison AU - Chandrasekaran, Sita S. AU - Charrez, Bérénice AU - Escajeda, Arturo M. AU - Son, Sungmin AU - Mcintosh, Roger AU - Bhuiya, Abdul AU - de León Derby, María Díaz AU - Switz, Neil A. AU - Armstrong, Maxim AU - Harris, Andrew R. AU - Prywes, Noam AU - Lukarska, Maria AU - Biering, Scott B. AU - Smock, Dylan C. J. AU - Mok, Amanda AU - Knott, Gavin J. AU - Dang, Qi AU - Van Dis, Erik AU - Dugan, Eli AU - Kim, Shin AU - Liu, Tina Y. AU - , AU - Harris, Eva AU - Stanley, Sarah A. AU - Lareau, Liana F. AU - Tan, Ming X. AU - Fletcher, Daniel A. AU - Doudna, Jennifer A. AU - Savage, David F. AU - Hsu, Patrick D. TI - Rapid, point-of-care molecular diagnostics with Cas13 AID - 10.1101/2020.12.14.20247874 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.14.20247874 4099 - http://medrxiv.org/content/early/2021/04/05/2020.12.14.20247874.short 4100 - http://medrxiv.org/content/early/2021/04/05/2020.12.14.20247874.full AB - Rapid nucleic acid testing is a critical component of a robust infrastructure for increased disease surveillance. Here, we report a microfluidic platform for point-of-care, CRISPR-based molecular diagnostics. We first developed a nucleic acid test which pairs distinct mechanisms of DNA and RNA amplification optimized for high sensitivity and rapid kinetics, linked to Cas13 detection for specificity. We combined this workflow with an extraction-free sample lysis protocol using shelf-stable reagents that are widely available at low cost, and a multiplexed human gene control for calling negative test results. As a proof-of-concept, we demonstrate sensitivity down to 40 copies/μL of SARS-CoV-2 in unextracted saliva within 35 minutes, and validated the test on total RNA extracted from patient nasal swabs with a range of qPCR Ct values from 13-35. To enable sample-to-answer testing, we integrated this diagnostic reaction with a single-use, gravity-driven microfluidic cartridge followed by real-time fluorescent detection in a compact companion instrument. We envision this approach for Diagnostics with Coronavirus Enzymatic Reporting (DISCoVER) will incentivize frequent, fast, and easy testing.Competing Interest StatementThe Regents of the University of California have filed patents related to this work. P.D.H. is a cofounder of Spotlight Therapeutics and serves on the board of directors and scientific advisory board, and is a scientific advisory board member to Vial Health and Serotiny. D.F.S. is a cofounder of Scribe Therapeutics and a scientific advisory board member of Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche.Funding StatementThis work was supported by the Shurl & Kay Curci Foundation, anonymous donors, Emergent Ventures, NIH, and DARPA under award N66001-20-2-4033. The views, opinions and/or findings expressed are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. We thank the National Institutes of Health for their support (P.D.H. R01GM131073, DP5OD021369, D.F.S. R01GM127463). J.A.D. is an Investigator of the Howard Hughes Medical Institute (HHMI). A.F. was supported by an NSF Graduate Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Adrienne Tanner from the Office for the Protection of Human Subjects (OPHS) at University of California, Berkeley determined that this project does not rise to the threshold definition of human subjects research and no IRB review was required, and so provided exemption for ethical approval. This exemption applies to the use of the human nasal swabs described in this version of the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences used are presented in the manuscript or supplementary text. Any additional data is available upon request.